Quick Takeaways
- GLMD - Galmed Pharmaceuticals Ltd. financial facts are built from SEC company filings data.
- Latest metrics period on this page: Q4 2025.
- Headline metric: Return On Equity -64%.
- Info
- Insider Trading
- Financials
Galmed Pharmaceuticals Ltd. financial metrics
Professional SEC-based dashboard for profitability, financial health, and growth with transparent scoring logic. Latest period: Q4 2025.
- Symbol
- GLMD on Nasdaq
- Location
- Ramat Gan, Israel
- Fiscal year end
- 31 December
- Latest financial report
- 31 Mar 2026
What Changed
- Return On Equity YoY change: <span class="text-green-600">+29%</span>.
- Most recent SEC facts end date: 31 Dec 2025.
Why This Matters
- This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
- Every metric card links to a deeper SEC-backed history page for verification.
Official SEC Source
Based on latest 10-Q/10-K
Facts and ratios are grounded in SEC company facts linked to the latest 10-Q/10-K cycle.
See Original FilingLatest SEC snapshot (2025-12-31) highlights Return On Equity -64.2%, Return On Assets -55.5%, and Current Ratio 6.55x.
Financial Quality Score
Transparent 0-100 scoring model based on profitability, financial health, and growth factors.
7.8/100
Weak Confidence low
Return On Equity
-64%
Metric score 0.0/100
Return On Assets
-56%
Metric score 0.0/100
Financial Health
- Current Ratio
- 6.55x
Strengths
No strong signals yet.
Watchpoints
Return On Equity, Return On Assets, and Current Ratio
Key metrics snapshot
Return On Equity
-64%
YoY: +29%
Industry median: -43% (n=675)
Return On Assets
-56%
YoY: +30%
Industry median: -47% (n=673)
Current Ratio
6.55x
YoY: -12%
Industry median: 3.39x (n=667)
NetIncomeLoss YoY
-37%
YoY:
Industry median: -0.93% (n=641)
Profitability
| Metric | Latest value | YoY change |
|---|---|---|
| Return On Equity | -64% | +29% |
| Return On Assets | -56% | +30% |
Financial Health
| Metric | Latest value | YoY change |
|---|---|---|
| Current Ratio | 6.55x | -12% |
Growth
| Metric | Latest value | YoY change |
|---|---|---|
| NetIncomeLoss YoY | -37% |
Share Metrics
| Metric | Latest value | YoY change |
|---|---|---|
| Entity Common Stock, Shares Outstanding | 6,581,390 | +298% |
| Common Stock, Shares, Outstanding | 6,581,390 | +295% |
| Common Stock, Value, Issued | $3,408,000 | +359% |
Additional Metrics
| Metric | Latest value | YoY change |
|---|---|---|
| Cash and Cash Equivalents, at Carrying Value | $3,985,000 | -14% |
| Marketable Securities, Current | $7,025,000 | -2.2% |
| Assets, Current | $18,627,000 | +16% |
| Assets | $18,627,000 | +0.69% |
| Accounts Payable, Current | $2,003,000 | +53% |
| Liabilities, Current | $2,845,000 | +31% |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | $303,000 | +27% |
| Retained Earnings (Accumulated Deficit) | $210,778,000 | -5.1% |
| Stockholders' Equity Attributable to Parent | $15,782,000 | -3.3% |
| Liabilities and Equity | $18,627,000 | +0.69% |
| Common Stock, Shares Authorized | 900,000,000 | 0% |
| Common Stock, Shares, Issued | 6,581,390 | +295% |
| Common Stock, Par or Stated Value Per Share | 1.8 | 0% |
| Deferred Tax Assets, Valuation Allowance | $49,666,000 | +16% |
| Deferred Tax Assets, Gross | $49,666,000 | +16% |
| Deferred Tax Assets, Operating Loss Carryforwards | $43,042,000 | +17% |
| Additional Paid in Capital | $223,455,000 | +3.2% |
How we score
This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.
| Metric | Weight | V1 threshold |
|---|---|---|
| ROIC | 20 | 5% to 20% |
| ROE | 15 | 8% to 25% |
| ROA | 10 | 2% to 10% |
| Operating Margin | 5 | 5% to 25% |
| Current Ratio | 12 | 1.0x to 2.0x |
| Quick Ratio | 8 | 0.8x to 1.5x |
| Debt to Equity | 10 | 0.3x to 2.0x (lower is better) |
| Revenue YoY | 10 | -10% to +20% |
| Net Income YoY | 10 | -10% to +20% |
How Calculated (standard_v1)
Metrics are computed with a market-consensus convention designed for cross-portal comparability.
- TTM Operating Income / TTM Revenues
- Current Assets / Current Liabilities (latest instant quarter)
- (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
- Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
- TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
- TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
- TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
- TTM Revenues YoY
- TTM Net Income YoY